Guiding Hypertension Management Using Different Blood Pressure Monitoring Strategies

Hypertension Clinical Trial

— GYMNs  

Official title:

A Randomized Controlled Trial Comparing Unattended Automated Office Blood Pressure vs. Home Blood Pressure vs. Central Blood Pressure Monitoring for the Management of Hypertension

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03578848
• Other study ID #: 2018-05-009A
• Status: Recruiting
• Phase: N/A
• Start date: June 6, 2018
• Est. completion date: March 1, 2020

Study information

• Verified date: September 2018
• Source: Taipei Veterans General Hospital, Taiwan
• Contact: Hao-Min Cheng, M.D., Ph.D.
• Phone: (886)-2-28757302
• Email: hmcheng[@]vghtpe.gov.tw
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients with uncontrolled or newly diagnosed hypertension will be randomized to have hypertension management decisions made on the basis of the unattended automated blood pressure (uAOBP) , home BP, and central BP monitoring. This study evaluates the optimal guiding strategy for hypertension will help define which BP monitoring is the most effective strategy to guide the clinical management of hypertension.

Description:

The traditional BP used for clinical practice, the office BP, is usually measured in a busy and hurry clinical environment, and interfered by the well-known confounding whitecoat effect. As such, unattended automated office BP monitoring (uAOBP) has been proposed as an effective solution and further promoted by Canadian physicians.

Nonetheless, out-of-office BP, home BP and ambulatory BP, remains the methodology of recommendation for the detection of whitecoat effect, and its prognostic value has been demonstrated to be superior to the traditional office BP. Home BP monitoring, with its ability to detect morning and masked hypertension and a better tolerability than ambulatory BP monitoring for long-term use, can therefore be considered as a strategy of choice to replace office BP monitoring for guiding hypertension management.

Moreover, BP measurements in the peripheral arteries cannot serve as direct substitutes for their central counterparts because of the long-recognized differences of blood pressure (BP) waveforms and values between the central aorta and peripheral arterial system. Thus, if the decisions on medication adjustment are made solely based brachial BP, there could be a considerable risk of over- or undertreatment.

Considering that there are many better strategies for guiding hypertension management than traditional office BP, there is an apparent need for investigating their comparative effectiveness and safety in the management of hypertension. The investigators hypothesized that home BP may be non-inferior to AOBP and central BP-guided intervention in reducing ambulatory BP and designed the present randomized controlled trial.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 252
• Est. completion date: March 1, 2020
• Est. primary completion date: June 1, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 90 Years

Eligibility

Inclusion Criteria:

• 20 to 90 years of age

• nonpregnant

• receiving antihypertensive therapy for uncomplicated essential hypertension and taking =1 but = 2 types antihypertensive drugs (to rule out complicated or resistant hypertension) or hypertension newly diagnosed by uAOBP (uAOBP >130 mmHg at screening visit)

Exclusion Criteria:

• Poor adherence to medication

• unable to conduct self-measurement blood pressure

• history of polycystic kidney disease

• congestive heart failure (a recent assessment of left ventricular ejection fraction < 40% prior to screening visit)

• chronic kidney disease with estimated glomerular filtration rate < 30 mL/min/1.73m2 (MDRD) at screening visit

• a recent document of severely abnormal left ventricular mass index (>59 g/m2.7 in women and >64 g/m2.7 in men) prior to screening visit

• secondary causes of hypertension

• uncontrolled hypertension (uAOBP >180/100 mm Hg at screening visit)

• history of severe aortic valve disease

• history of upper limb obstructive atherosclerosis

• history of atrial fibrillation

• BP Differences more than 5 mmHg between both arms at screening visit

Related Conditions & MeSH terms

• Hypertension

Intervention

Device:
• uAOBP
For the uAOBP and CBP, the measurements will be conducted in a quiet room without the presence of clinical personnel. Patients will be seated in a quiet room without talking and taken as an average of 3 measurements with an automated device (HEM-907, Omron Healthcare, Lake Forest, IL) that has been preset to wait 5 minutes before measurements. Simultaneously, the central BP will be measured in the other upper arm. (WatchBP Office Central; Microlife AG, Widnau, Switzerland). The determination of the right or left upper arm for uAOBP or central BP will be made in a random order by computer generated random codes before the enrollment.
• Home BP
As for the home BP measurements, a validated device (WatchBP Home; Microlife AG, Widnau, Switzerland) will be provided for all subjects allocated to the home BP arm to measure their BP at home. Subjects are requested to take BP in the morning (within 2 hours after awakening) and afternoon before meals for 7 consecutive days before the scheduled clinical visits. BP in the first day of the measurements will be discarded and an average of home BP (all BP reading and BP in the morning and in the afternoon) will be generated and provided for clinicians to guide their treatment.
• CBP
For the uAOBP and CBP, the measurements will be conducted in a quiet room without the presence of clinical personnel. Patients will be seated in a quiet room without talking and taken as an average of 3 measurements with an automated device (HEM-907, Omron Healthcare, Lake Forest, IL) that has been preset to wait 5 minutes before measurements. Simultaneously, the central BP will be measured in the other upper arm. (WatchBP Office Central; Microlife AG, Widnau, Switzerland). The determination of the right or left upper arm for uAOBP or central BP will be made in a random order by computer generated random codes before the enrollment.

Locations

Country	Name	City	State
Taiwan	Taipei Veterans General Hospital	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
Taipei Veterans General Hospital, Taiwan

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	24 hour mean ambulatory systolic blood pressure	The change of 24 hour mean ambulatory systolic blood pressure (SBP)	3 months
Secondary	24 hour mean ambulatory diastolic blood pressure	The change of 24 hour mean ambulatory diastolic blood pressure (DBP)	3 months
Secondary	left ventricular mass	decrease of left ventricular mass	12 months
Secondary	SBP and DBP	change of SBP/DBP measured by uAOBP monitoring, home BP monitoring, or central BP monitoring	12 months